Prospects For Pfizer/Medivation's Dimebon Dashed By Phase III Flop
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The Phase III failure of the high-profile Alzheimer's disease drug dimebon is a setback not only for Alzheimer's drug development, but also for Pfizer, which very much needs pipeline successes to offset upcoming patent losses, and for Medivation, whose near-term future hinges on the drug